BR112019022358A2 - métodos para quantificar proteínas inibidoras inter-alfa - Google Patents

métodos para quantificar proteínas inibidoras inter-alfa Download PDF

Info

Publication number
BR112019022358A2
BR112019022358A2 BR112019022358-4A BR112019022358A BR112019022358A2 BR 112019022358 A2 BR112019022358 A2 BR 112019022358A2 BR 112019022358 A BR112019022358 A BR 112019022358A BR 112019022358 A2 BR112019022358 A2 BR 112019022358A2
Authority
BR
Brazil
Prior art keywords
iaip
individual
fact
species
agent
Prior art date
Application number
BR112019022358-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Lim Yow-Pin
Spero Denice
Original Assignee
Prothera Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothera Biologics, Inc. filed Critical Prothera Biologics, Inc.
Publication of BR112019022358A2 publication Critical patent/BR112019022358A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112019022358-4A 2017-04-25 2018-04-25 métodos para quantificar proteínas inibidoras inter-alfa BR112019022358A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762490003P 2017-04-25 2017-04-25
US62/490,003 2017-04-25
US201862614333P 2018-01-05 2018-01-05
US62/614,333 2018-01-05
PCT/US2018/029436 WO2018200722A1 (en) 2017-04-25 2018-04-25 Methods for quantifying inter-alpha inhibitor proteins

Publications (1)

Publication Number Publication Date
BR112019022358A2 true BR112019022358A2 (pt) 2020-05-19

Family

ID=63920445

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019022358-4A BR112019022358A2 (pt) 2017-04-25 2018-04-25 métodos para quantificar proteínas inibidoras inter-alfa

Country Status (10)

Country Link
US (2) US20200057077A1 (https=)
EP (1) EP3615937B1 (https=)
JP (2) JP7293128B2 (https=)
KR (1) KR102587810B1 (https=)
CN (1) CN110691973B (https=)
AU (1) AU2018258466B2 (https=)
BR (1) BR112019022358A2 (https=)
CA (1) CA3061164A1 (https=)
IL (1) IL270069B1 (https=)
WO (1) WO2018200722A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
US20210393750A1 (en) * 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
US20230055086A1 (en) * 2021-08-19 2023-02-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins
CN114088949B (zh) * 2021-11-11 2024-09-27 王南 乌司他丁前体用于检测炎症的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4839298A (en) 1986-02-14 1989-06-13 Akzo N.V. Virus inactivating diluents used in immunoassays
EP0367090B1 (en) 1988-11-01 1994-01-12 Schwarz Pharma Ag Lyophilized MDM composition and method of making it
GB8928501D0 (en) 1989-12-18 1990-02-21 Unilever Plc Reagents
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US6313091B1 (en) 1995-07-20 2001-11-06 New York University Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method
JP4217717B2 (ja) * 1996-07-16 2009-02-04 生化学工業株式会社 血清由来ヒアルロナン結合性タンパク質−ヒアルロン酸結合体の測定法および測定キット
AU5134799A (en) 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6489128B1 (en) 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
EP1326893A2 (de) 2000-10-13 2003-07-16 Octapharma AG Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
DE60120500T2 (de) 2000-12-08 2007-06-06 Genentech, Inc., South San Francisco In Knorpelgeweben stark exprimiertes Gen
GB0114709D0 (en) 2001-06-15 2001-08-08 Pfizer Ltd Stabilised formulations of amlodipine maleate
US20030027848A1 (en) 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
AU2003226021B2 (en) 2002-03-26 2008-07-17 Teva Pharmaceutical Industries Ltd. Drug microparticles
JP4180911B2 (ja) 2002-12-27 2008-11-12 生化学工業株式会社 新規酵素活性測定方法
WO2004082615A2 (en) 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
CN1160123C (zh) 2003-05-26 2004-08-04 广东天普生化医药股份有限公司 乌司他丁用于治疗严重急性呼吸综合征的用途及其药物组合物
WO2005030252A1 (en) 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP3127916A1 (en) 2004-06-07 2017-02-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US7939282B2 (en) * 2004-10-21 2011-05-10 Rhode Island Hospital Methods for detecting sepsis
CN101160133B (zh) 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CN103142650B (zh) 2004-11-05 2016-05-11 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
WO2008067655A1 (en) 2006-12-05 2008-06-12 Q6 Biomaterials Inc. Biocompatible hydrogel-based scaffolds
US8026345B2 (en) 2007-01-08 2011-09-27 Hoffmann-La Roche Inc. Characterization and identification of unique human adiponectin isoforms and antibodies
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2009020481A2 (en) 2007-05-08 2009-02-12 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
CN106928346B (zh) * 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
HRP20160760T1 (hr) 2008-07-18 2016-08-12 A1M Pharma Ab Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina
US20110236381A1 (en) 2008-12-10 2011-09-29 Stavros Garantziotis Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
WO2011150944A1 (en) 2010-06-04 2011-12-08 Trifoilium Aps Trefoil factors (tff) for the treatment of chronic pulmonary diseases
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof
JP2013101047A (ja) 2011-11-08 2013-05-23 Nagasaki Univ １４−３−３蛋白γアイソフォーム特異的ＥＬＩＳＡ
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2015071402A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
JP6183174B2 (ja) 2013-11-26 2017-08-23 ユーハ味覚糖株式会社 ヒアルロン酸高含有固形食品及びその製造方法
WO2016138476A1 (en) 2015-02-26 2016-09-01 Mycotechnology, Inc. Methods for lowering gluten content using fungal cultures
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
US20210393750A1 (en) 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Also Published As

Publication number Publication date
AU2018258466A1 (en) 2019-12-05
IL270069A (https=) 2019-12-31
EP3615937B1 (en) 2026-01-28
KR102587810B1 (ko) 2023-10-11
JP2023085249A (ja) 2023-06-20
KR20200010262A (ko) 2020-01-30
CA3061164A1 (en) 2018-11-01
JP2020517967A (ja) 2020-06-18
EP3615937A4 (en) 2021-08-11
US20200057077A1 (en) 2020-02-20
WO2018200722A1 (en) 2018-11-01
EP3615937C0 (en) 2026-01-28
AU2018258466B2 (en) 2025-05-22
CN110691973B (zh) 2024-11-29
EP3615937A1 (en) 2020-03-04
US12265090B2 (en) 2025-04-01
JP7293128B2 (ja) 2023-06-19
US20220099684A1 (en) 2022-03-31
CN110691973A (zh) 2020-01-14
IL270069B1 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
US12265090B2 (en) Inter-alpha inhibitor proteins
JP7441662B2 (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
ES2935060T3 (es) Procedimiento para la determinación de los agregados de proteínas utilizando la superficie FIDA
BR112016008970B1 (pt) Método de ativação ex vivo, método para avaliar ativação plasmática e ensaio ex vivo
US20200271647A1 (en) Biomarkers for predicting prognosis of kidney disease
JP2019023642A (ja) 腎機能の評価装置、腎疾患の合併症の発症の予測装置、およびリン摂取量推定装置
Zhang et al. Serum levels of alpha-smooth muscle actin and c-Met as biomarkers of the degree of severity of Henoch–Schonlein purpura nephritis
US7939282B2 (en) Methods for detecting sepsis
US20230055086A1 (en) Inter-alpha inhibitor proteins
CN114364984A (zh) 一种诊断或监测儿科患者的肾功能或诊断肾功能障碍的方法
EA045401B1 (ru) Способы количественного определения интер-альфа ингибиторных белков
CN107106014B (zh) 5-甲氧基色胺酸作为发炎疾病诊断试剂的用途
Chen et al. Rapid Detection of Inter-alpha Inhibitor Proteins in Neonatal Sepsis and Necrotizing Enterocolitis
AYVAZ et al. Fecal Calprotectin Level in Patients with Rosacea: Gut Inflammation May Be Associated with the Type of Rosacea, A Case-Control Study.
US8911956B2 (en) Methods of use for an immunoassay detecting fragment Ba
BR112017021850B1 (pt) Métodos para detectar clusterina específica do rim, doença renal, insuficiência renal ou danos nos rins, para distinguir mais uma isoforma de clusterina a partir de outros tipos de isoformas dela e para melhorar a detecção de clusterina e de isoformas dela, kit e complexo
BR122023015873B1 (pt) Método in vitro para avaliar um tratamento de um distúrbio mediado por calicreína plasmática (pkal) em um sujeito
BR112015017195B1 (pt) Método e kit para detectar inibidor de protease c1 de plasma
BR122023011051B1 (pt) Método in vitro para avaliar um tratamento de um distúrbio mediado por calicreína plasmática

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]